Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 21-30 of 193 for Skin cancer

Edit search filters
  1. A Study to Assess LXH254 in Patients with Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma

    Rochester, MN

  2. Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy

    Rochester, MN

  3. Melanoma Prevention through Education

    Scottsdale/Phoenix, AZ

  4. A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection

    Jacksonville, FL

  5. MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

    Rochester, MN

  6. Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

    Rochester, MN

  7. Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

    Scottsdale/Phoenix, AZ

  8. Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

    Rochester, MN

  9. A Phase 3 Study to Evaluate Petosemtamab Compared with Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

.

Mayo Clinic Footer